Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of the...
Kira Sheinerman Secures Board Rights at Niki BioSolutions with 51.56% Stake
Aptorum Group plans 1-for-10 reverse stock split ahead of DiamiR merger
Aptorum Group Provides Update on DiamiR Biosciences Merger | APM Stock News
Aptorum, DiamiR set to close all-stock merger before fiscal 2027, rebrand as Niki BioSolutions
Aptorum amends 6-K to extend DiamiR merger termination date to July 31, 2026
Aptorum announces DiamiR-AlzLabs collaboration on blood-based Alzheimer’s biomarkers